EnteroBiotix, a microbiome therapeutics company tucked into Scotland's central belt, closed a £19 million financing round last week with an ambitious goal: running what it claims will be the largest full-spectrum microbiome trial ever conducted for irritable bowel syndrome. The Glasgow-area firm plans to enroll 300 patients in a Phase 2b study of its oral capsule, a therapeutic cocktail designed to recalibrate the gut's microbial ecosystem.
That's a sizable bet on a field that has seen its share of setbacks. Microbiome-based therapies have generated breathless headlines for years, though translating early promise into approvable drugs has proven stubbornly difficult outside a handful of narrow indications. EnteroBiotix is hoping its "full-spectrum" approach—essentially casting a wider bacterial net than competitors focused on a few select strains—will break through where others have stumbled.
The April 29 round was co-led by Thairm Bio, a repeat backer, and the Scottish National Investment Bank, a government-backed institution that has become a reliable presence in EnteroBiotix's cap table. New and existing investors joined, though the company didn't disclose their names. The fresh capital pushes EnteroBiotix's total fundraising to more than £65 million as of early May 2026, since Dr. James McIlroy, a physician-turned-entrepreneur with degrees from Edinburgh and Aberdeen, founded the company in 2017.
A Trial Built on Earlier Signals
The money will bankroll the RISE trial—short for Restoring Intestinal Symbiosis for Efficacy in IBS, a randomized, double-blind, placebo-controlled study spanning sites in the UK and US. Patients suffering from IBS with constipation will receive four single doses of the experimental drug, called EBX-102-02, administered at clinic visits over a nine-week window. Researchers will measure symptom severity at the 14-week mark as the primary endpoint.
The trial design splits participants into three arms: one receiving a pooled multi-donor formulation, another getting a single-donor version, and a third on placebo. First dosing is anticipated in Q2 2026, with topline efficacy results expected in the second half of 2027. That's a timeline the company is betting will validate Phase 2a data released in January, which showed what EnteroBiotix characterized as "clear efficacy signals" across key measures in both constipation-predominant and diarrhea-predominant IBS subtypes.
Industry watchers remain cautiously curious. The earlier TrIuMPH study was smaller and designed primarily to inform dose selection and formulation strategy rather than provide definitive proof of efficacy. The Phase 2b program will carry considerably more weight—and scrutiny.
The Microbiome's Moment, Maybe
EnteroBiotix is entering a crowded but still largely unproven space. IBS affects somewhere between 5% and 10% of people globally, depending on how strictly you define it, and treatment options have long been frustratingly limited. Dietary changes help some patients; pharmaceutical interventions tend to address symptoms rather than underlying causes. That gap has made the gut microbiome an attractive target for biotechs chasing both scientific validation and commercial opportunity.
The company's oral capsule stands apart, at least on paper, from narrower microbial therapies that focus on a handful of bacterial strains. Whether deploying hundreds of species confers a meaningful advantage—or simply introduces more variables to manage—is the kind of question a well-powered Phase 2b trial should help answer.
EnteroBiotix operates from a 20,000-square-foot facility in Bellshill, just outside Glasgow, where it holds a Manufacturer's Investigational Medicinal Product license from the UK's Medicines and Healthcare products Regulatory Agency for good manufacturing practice production. The company has also advanced programs in liver cirrhosis and complications stemming from bone marrow transplants, though IBS remains its lead indication.
Thairm Bio's involvement runs deep. The investment firm led EnteroBiotix's $21.5 million Series A back in September 2021 and participated again in a £27 million Series B in April 2024. The Scottish National Investment Bank has similarly shown up across multiple rounds, part of a broader push by the Scottish government to nurture life sciences companies within its borders.
With patient enrollment about to begin and a 2027 data readout on the horizon, EnteroBiotix is positioning itself for a defining moment. The microbiome field has burned through hype cycles before. Whether this Glasgow upstart can deliver the kind of rigorous clinical evidence that wins over regulators—and eventually, payers—will depend on what those 300 IBS patients reveal over the next 18 months.
